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A B S T R A C T
Epilepsy and migraine are episodic neurological disorders with marked co-morbidity, making migraine
common among epileptic patients. Conversely, several antiepileptic drugs (AEDs) are used as migraine-
preventive medication. Cortical spreading depression (CSD) represents a transient suppression of
bioelectric activity and is considered a key event in migraine and stroke. This study assessed the novel
AED candidate brivaracetam (BRV) vs. the chemically related AED levetiracetam in a rat neocortical slice
model allowing consistent quantiﬁcation of drug effects on CSD. CSD episodes were regularly elicited on
slices upon delivery of calibrated KCl drops and were recorded via two micropipette electrodes. After
control CSDs, the drug was added to the perfusion and ﬁve subsequent CSDs were elicited during drug
perfusion. Effects were assessed via CSD amplitude (Ampl) and duration at half-amplitude (D1/2). BRV, 10
and 32 mM reduced the Ampl and transiently the D1/2. Levetiracetam, 32 and 100 mM had no effect on
either Ampl or D1/2. The anti-CSD effect of BRV in this in vitro model might suggest a potential anti-
migraine activity of this compound, which warrants further investigation.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy and migraine—chronic disorders characterized by
recurrent, episodic neurological dysfunction—are strongly asso-
ciated co-morbid conditions.1 Their pathophysiological relation
were already ‘‘long recognized’’ at the end of 19th century2 and a
wealth of subsequent epidemiological evidence, summarized by
Haut et al.3 documented a bidirectional association of these
families of neurological disorders, suggesting possible common
pathophysiological mechanisms.4 Similarly to epilepsy, the neu-
robiology of migraine is incompletely deﬁned.5 However, the
concept of migraine as caused by a state of central neuronal
hyperexcitability got consistent support from functional MRI
evidence showing that the migraine aura—a visual hallucination/
illusion preceding the headache in 20% of migraine cases—is
generated by a cortical spreading depression (CSD) event in the
visual cortex.6
CSD is a wave of deep transient suppression of brain bioelectric
activity, propagating at mm/min velocity. It can be elicited in the
whole brain of anesthetized animals, as well as in rodent (e.g. Ref.
7) and human8 neocortical slices in vitro by noxious maneuvers
such as local application of KCl. Already since its discovery in 1944
by Lea˜o, CSD was assumed to be associated with migraine aura.* Corresponding author at: UCB Pharma SA, Chemin du Foriest, B-1420 Braine-
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doi:10.1016/j.seizure.2009.01.002Recently, it was shown that CSD activates trigeminal afferents that
generate the headache upon causing inﬂammation in the pain-
sensitive meninges,9 so that CSD is the most probable primary
event not only in (the less frequent) migraine with aura, but also in
(the more frequent) migraine without aura.5
The concept that brain hyperexcitability causes susceptibility for
triggering migraine attacks provides a rational basis for using the
antiepileptic drugs (AEDs) in migraine prophylaxis.10 Several AEDs
(valproate, topiramate, gabapentin, lamotrigine) are indeed used as
migraine-preventive medication4 and animal studies reported CSD
suppression by migraine-prophylactic treatments.11,12
Brivaracetam (BRV; (2S)-2-[(4R)-2-oxo-4-propylpyrrolidinyl]-
butanamide) is a newer pyrrolidone derivative, structurally related
to levetiracetam (LEV). BRV displays a higher afﬁnity than LEV to its
binding site synaptic vesicle protein 2A (SV2A)13 and has higher
potency and efﬁcacy than levetiracetam in animal models of
epilepsy both in vitro and in vivo.14 Currently, BRV is in development
as anAED.15Herewe report the results of assessing BRV in a recently
described rat neocortical slice model of CSD16 vs. LEV, taken as a
comparator in view of its chemical kinship with BRV.
2. Materials and methods
The in vitro slice model used in this study was recently
characterized in detail.16 In brief, brain neocortical slices were
prepared from male Sprague–Dawley rats (IFFA CREDO, Brussels,
Belgium), between 5 and 7 weeks of age, according to standard
procedures. The brain, quickly removed from the deeply anesthe-vier Ltd. All rights reserved.
Fig. 1. The model of regularly inducing CSD episodes in rat neocortical slices in vitro and of their quantifying. The relative positioning of the two recording micropipettes
(‘‘Record A’’ and ‘‘Record B’’), of the KCl-dropping pipette and of the stimulation electrode is shown (upper left) on a drawn of coronal section through the rat brain at the level
of primary somato-sensory cortex,20 where the slices used in this study were cut. The DC ﬁeld potentials recorded at ‘‘A’’ and ‘‘B’’, when a KCl droplet elicits a CSD event, are
illustrated at upper right, the two interrupted lines superposed on the records highlighting the delay between CSD appearance at the two recording points. The lower scheme
depicts the time-course of the protocol used.
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(ACSF), composed of (inmM): NaCl 126, KCl 3, CaCl2 2.4, MgCl2 1.3,
NaH2PO4 1.24, NaHCO3 26, and D-glucose 10. Coronal slices, 350-
mm thick, were cut at the level of primary somato-sensory cortex
with a Leica VT1000S vibratome (Leica, Germany), in refrigerated
(<4 8C) and oxygenated (95% O2, 5% CO2) ACSF. The slices were
kept for 2 h at 32 8C in oxygenated ACSF. The procedures were
approved by the local ethics committee for animal experimenta-
tion, in accordance with European Communities Council Directive
86/609/EEC, and all efforts were done to minimize the number of
sacriﬁced animals and their pain.
The recordings were done in interface chambers, at 32 8C, via
two micropipette electrodes, placed on the cortical layers I–II of
the slice, at points ‘‘A’’ and ‘‘B’’ spaced about 2.5 mm (Fig. 1, upper
left). A stimulating bipolar Pt wire electrode was placed on the
cortical layers V–VI, to elicit ﬁeld potentials (recorded via the
micropipettes ‘‘A’’ and ‘‘B’’) for checking slice responsiveness upon
evoking AC ﬁeld potentials, visualized on a Tektronix TDS
oscilloscope. At 1.5 mm distance from the recording micropip-
ette ‘‘A’’, also on the cortical layers I–II, was placed another
micropipette, with the tip 10 mm, from which droplets of KCl,
3 Mwere delivered to induce CSD. The nl-volume of KCl droplet
was set via the open time (s) of the electric microvalve of a
homemade picoliter dispenser.
CSD episodes were acquired via a software which measures on-
line the amplitude (Ampl) and duration at half-amplitude (D1/2) of
the characteristic DC ﬁeld potentials (Fig. 1, upper right). The DC
ﬁeld potentials from ‘‘A’’ and ‘‘B’’ were also recorded by a two-
channel Gould TA240 recorder, as a paper trace synopsis of the
whole experiment. Once the size of the KCl droplet inducing CSD at
both ‘‘A’’ and ‘‘B’’ points was found, it was kept throughout therecording. Three CSD episodes were recorded, at 20-min intervals,
with the slice perfusedwith standard ACSF, to conﬁrm the stability
and assess responsiveness uniformity among the groups of slices.
The drug was added to the perfusion ﬂuid 20 min after the third
CSD episode, then, after other 20 min ﬁve subsequent CSD episodes
were induced, at 20-min intervals, in the presence of the drug
(protocol scheme in Fig. 1, bottom).
BRV and LEV (both from UCB Pharma) have been dissolved in
plain ACSF. Drug concentrations were chosen as reported active on
neurons and brain slices in vitro: BRV—10 and 32 mM,14,17 and
LEV—32 and 100mM.18,19
To unravel putative drug effects, the post-drug values of CSD
Ampl and D1/2 were normalized with respect to the pre-drug level
(at the third CSD episode) in the same slice. The bar graphs in the
section Results show mean  S.E.M. of Ampl and D1/2 of the CSD
episodes elicited in parallel groups of drug-treated and control slices.
The statistical signiﬁcance of the differences between parallel groups
of slices was assessed with one-tailed t-test.
3. Results
Application of identical droplets of KCl, 3 M at 20-min intervals
consistently induced CSD events, recordable extracellularly as
slow (up to 1-min duration) DC transients with a characteristic
shape, appearing at the closer electrode ‘‘A’’, then—after a
propagation latency—at the electrode ‘‘B’’ (Fig. 1, upper right).
As the CSDs successively elicited at 20-min intervals present a
facilitation tendency, better expressed on the duration,16 the
graphs in Figs. 2 and 3 show the normalized Ampl and D1/2 of the
ﬁrst and the last post-drug CSD episodes, respectively termed
‘‘Early’’ and ‘‘Late’’.
Fig. 2. Effect of brivaracetam (BRV), 10 and 32mM in the perfusion ﬂuid of rat
neocortical slices on the amplitude (Ampl) and duration at half-amplitude (D1/2) of
the ‘‘Early’’ (i.e. the ﬁrst post-drug) and ‘‘Late’’ (i.e. the ﬁfth post-drug) CSD events,
recorded at the electrodes ‘‘A’’ (upper graph) and ‘‘B’’ (lower graph). The bars
(mean  S.E.M.) show the parameters normalized with respect to pre-BRV values, i.e.
at the third CSD episode, in groups of eight slices per group. Signiﬁcant (P < 0.05)
differences vs. the respective control group are indicated with ($).
Fig. 3. Effect of levetiracetam (LEV), 32 and 100mM in the perfusion ﬂuid of rat
neocortical slices on the amplitude (Ampl) and duration at half-amplitude (D1/2) of
the ‘‘Early’’ and ‘‘Late’’ CSD events, recorded at the electrodes ‘‘A’’ (upper graph) and
‘‘B’’ (lower graph). The bars (mean  S.E.M.) show the parameters normalized with
respect to pre-LEV values, in groups of six slices per group. No difference vs. the
respective control group was statistically signiﬁcant.
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Ampl and transiently the D1/2 of the CSD episodes, recorded at both
recording points. However, a concentration-dependence was
expressed only partially. In contrast to BRV, LEV did not modify
either Ampl or D1/2 of CSDs, at any of the two recording points
(Fig. 3).
4. Discussion
The proven relevance of the CSD phenomenon in migraine
pathology5,11,12 entails inferring that the noteworthy reductions of
both amplitude and duration of CSDs, produced by BRV in this
model (Fig. 2) might conceivably express a migraine-prophylactic
potential of this drug. Migraine is frequent in patients with
epilepsy1,21 and it was shown that migraine with aura entails in
children a substantial increased risk to develop epilepsy.22
Consequently, conﬁrming a possible anti-migraine activity of a
forthcoming AED deserves further investigation, in view of the
potential relevance for both migraine and epilepsy therapy.
The CSD-depressing effect of BRV herein reported is in principle
reminiscent of the migraine-preventing capabilities of other AEDs,
such as gabapentin, lamotrigine, topiramate and valproate, though
the results of various clinical studies assessing those AEDs in
migraine prophylaxis are sometimes conﬂicting and the prophy-
lactic treatment of migraine hardly reaches 50% efﬁcacy (forreview, see Ref. 23). The difference between the partial anti-CSD
activity of BRV (Fig. 2) and the full CSD-blocking effect of the NMDA
antagonist MK-801 in our model16 suggests that the targets of BRV
might be less important for CSD elicitation than the NMDA
channel. A similar conclusion was reached years ago in the case of
other AEDs.24 A point worth noticing, however, is that acute drug
application upon perfusion on slices from untreated animals, as in
the current in vitro model, is not meant to mimic the chronic
treatment underlying a migraine-preventing activity. Thus, even a
transient and partial effect detected upon such short-term
exposure might, nevertheless, be a fair hint of putative
migraine-preventing activity. This conjecture is supported by
the recent report that several drugs widely prescribed for migraine
prophylaxis, including the AEDs topiramate and valproate,
inhibited CSD in anesthetized rats in vivo when chronically
administered, longer treatments producing stronger CSD suppres-
sion, whereas the acute treatment was ineffective.12
LEV, assessed as a comparator only in view of its chemical
kinship with BRV, was devoid of effect on CSD in this model. The
lack of anti-CSD effect of LEV is congruentwith the absence of other
pathologies than epilepsy from the registered indications of this
AED25 and also points to some mechanistic difference between
BRV and LEV, beyond their different SV2A afﬁnities. Indeed, BRV
has been reported to inhibit neuronal Na+ channels,17 at difference
from LEV that does not act on neuronal Na+ current.26 Therefore, it
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ing effect of Na+ channels inhibition by BRV not only contributes to
the anticonvulsant effects of this drug,well expressed in vivo and in
vitro,14 but also might entail a migraine-preventive activity.
Conﬁrming this conjecture is, however, hampered by the scarcity
of the current knowledge of the mode of action of most drugs used
in migraine prophylaxis, and it goes beyond the scope of this
exploratory study.
In summary, this study has shown that the novel AED candidate
BRV reduces CSD episodes regularly elicited in rat neocortical slices
in vitro, an effect that might suggest an anti-migraine potentiality
of this compound, deserving further investigation.
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